Inrebic (fedratinib), a new inhibitor drug, received a positive opinion for the treatment of primary myelofibrosis and of myelofibrosis secondary to polycythaemia vera or essential thrombocythaemia by the European Medicines Agency’s (EMA) Human Medicines Committee (CHMP) at its December 2020 meeting.
Please read more: https://www.ema.europa.eu/en/medicines/human/summaries-opinion/inrebic
